CYP4F2

Summary

Gene Symbol: CYP4F2
Description: cytochrome P450 family 4 subfamily F member 2
Alias: CPF2, phylloquinone omega-hydroxylase CYP4F2, 20-HETE synthase, 20-hydroxyeicosatetraenoic acid synthase, CYPIVF2, arachidonic acid omega-hydroxylase, cytochrome P450 4F2, cytochrome P450, family 4, subfamily F, polypeptide 2, cytochrome P450, subfamily IVF, polypeptide 2, cytochrome P450-LTB-omega, leukotriene-B(4) 20-monooxygenase 1, leukotriene-B(4) omega-hydroxylase 1
Species: human
Products:     CYP4F2

Top Publications

  1. Borgiani P, Ciccacci C, Forte V, Sirianni E, Novelli L, Bramanti P, et al. CYP4F2 genetic variant (rs2108622) significantly contributes to warfarin dosing variability in the Italian population. Pharmacogenomics. 2009;10:261-6 pubmed publisher
    ..Recently, a new SNP within the CYP4F2 gene was found associated with warfarin dose in the USA...
  2. Fu Z, Nakayama T, Sato N, Izumi Y, Kasamaki Y, Shindo A, et al. A haplotype of the CYP4F2 gene associated with myocardial infarction in Japanese men. Mol Genet Metab. 2009;96:145-7 pubmed publisher
    This study assessed associations between the CYP4F2 gene and myocardial infarction (MI), using a haplotype-based case-control study of 234 MI patients and 248 controls genotyped for 5 single-nucleotide polymorphisms (rs3093105, rs3093135, ..
  3. Cha P, Mushiroda T, Takahashi A, Kubo M, Minami S, Kamatani N, et al. Genome-wide association study identifies genetic determinants of warfarin responsiveness for Japanese. Hum Mol Genet. 2010;19:4735-44 pubmed publisher
    ..identified single-nucleotide polymorphism (SNP) rs2108622 [cytochrome P450, family 4, subfamily F, polypeptide 2 (CYP4F2)] as a genetic determinant of warfarin responsiveness for Japanese...
  4. Zeng W, Zheng Q, Huang M, Cen H, Lai Y, Chen W, et al. Genetic polymorphisms of VKORC1, CYP2C9, CYP4F2 in Bai, Tibetan Chinese. Pharmazie. 2012;67:69-73 pubmed
    VKORC1, CYP2C9 and CYP4F2 are three critical genes associated with inter-individual variation of warfarin dose...
  5. Fava C, Montagnana M, Danese E, Sjögren M, Almgren P, Guidi G, et al. The functional variant V433M of the CYP4F2 and the metabolic syndrome in Swedes. Prostaglandins Other Lipid Mediat. 2012;98:31-6 pubmed publisher
    ..The cytochrome P450 isoform 4F2 (CYP4F2) is involved in renal production of 20-hydroxyeicosatethraenoic acid (20-HETE), a natriuretic substance associated ..
  6. Stec D, Roman R, Flasch A, Rieder M. Functional polymorphism in human CYP4F2 decreases 20-HETE production. Physiol Genomics. 2007;30:74-81 pubmed
    ..The cytochrome P450 4F2 (CYP4F2) gene encodes for the major CYP enzyme responsible for the synthesis of 20-HETE in the human kidney...
  7. Ward N, Tsai I, Barden A, van Bockxmeer F, Puddey I, Hodgson J, et al. A single nucleotide polymorphism in the CYP4F2 but not CYP4A11 gene is associated with increased 20-HETE excretion and blood pressure. Hypertension. 2008;51:1393-8 pubmed publisher
    ..A guanine-to-adenine polymorphism in the CYP4F2 gene was associated with a reduction in 20-hydroxyeicosatetraenoic acid production in vitro...
  8. McDonald M, Rieder M, Nakano M, Hsia C, Rettie A. CYP4F2 is a vitamin K1 oxidase: An explanation for altered warfarin dose in carriers of the V433M variant. Mol Pharmacol. 2009;75:1337-46 pubmed publisher
    ..The V433M polymorphism (rs2108622) in CYP4F2 has also been associated with warfarin dose and speculatively linked to altered VK1 metabolism...
  9. Lee M, Chen C, Chou C, Lu L, Chuang H, Chen Y, et al. Genetic determinants of warfarin dosing in the Han-Chinese population. Pharmacogenomics. 2009;10:1905-13 pubmed publisher
    ..SNPs in 13 genes (VKORC1, CYP2C9, CYP2C18, PROC, APOE, EPHX1, CALU, GGCX, ORM1, ORM2, factor II, factor VII and CYP4F2) and tested their associations with warfarin dosing with univariate and multiple regression analysis...

More Information

Publications120 found, 100 shown here

  1. Sagreiya H, Sagrieya H, Berube C, Wen A, Ramakrishnan R, Mir A, et al. Extending and evaluating a warfarin dosing algorithm that includes CYP4F2 and pooled rare variants of CYP2C9. Pharmacogenet Genomics. 2010;20:407-13 pubmed publisher
    ..clinical and pharmacy records; we genotyped single nucleotide polymorphisms relevant to the VKORC1, CYP2C9, and CYP4F2 genes using integrated fluidic circuits made by Fluidigm...
  2. Cen H, Zeng W, Leng X, Huang M, Chen X, Li J, et al. CYP4F2 rs2108622: a minor significant genetic factor of warfarin dose in Han Chinese patients with mechanical heart valve replacement. Br J Clin Pharmacol. 2010;70:234-40 pubmed publisher
    ..Recent studies among Caucasians showed that polymorphisms of CYP4F2 also play a role in warfarin pharmacogenetics...
  3. Munshi A, Sharma V, Kaul S, Al Hazzani A, Alshatwi A, Shafi G, et al. Association of 1347 G/A cytochrome P450 4F2 (CYP4F2) gene variant with hypertension and stroke. Mol Biol Rep. 2012;39:1677-82 pubmed publisher
    Genetic variants of cytochrome P450 4F2 (CYP4F2) gene have been suggested to be risk factors for hypertension, cardiovascular diseases and stroke...
  4. Kikuta Y, Miyauchi Y, Kusunose E, Kusunose M. Expression and molecular cloning of human liver leukotriene B4 omega-hydroxylase (CYP4F2) gene. DNA Cell Biol. 1999;18:723-30 pubmed
    Human liver leukotriene B4 (LTB4) omega-hydroxylase (CYP4F2) plays an important role in the metabolic inactivation and degradation of LTB4, a potent mediator of inflammation...
  5. Caldwell M, Awad T, Johnson J, Gage B, Falkowski M, Gardina P, et al. CYP4F2 genetic variant alters required warfarin dose. Blood. 2008;111:4106-12 pubmed publisher
    ..A DNA variant (rs2108622; V433M) in cytochrome P450 4F2 (CYP4F2) was associated with warfarin dose in 3 independent white cohorts of patients stabilized on ..
  6. Deng S, Zhu G, Liu F, Zhang H, Qin X, Li L, et al. CYP4F2 gene V433M polymorphism is associated with ischemic stroke in the male Northern Chinese Han population. Prog Neuropsychopharmacol Biol Psychiatry. 2010;34:664-8 pubmed publisher
    b>CYP4F2 is a member of the cytochrome P450 enzymes and is responsible for metabolizing arachidonic acid to 20-hydroxyeicosatetraenoic acid (20-HETE); 20-HETE plays a role in the regulation of vascular tone in the cerebral, coronary, and ..
  7. Wells P, Majeed H, Kassem S, Langlois N, Gin B, Clermont J, et al. A regression model to predict warfarin dose from clinical variables and polymorphisms in CYP2C9, CYP4F2, and VKORC1: Derivation in a sample with predominantly a history of venous thromboembolism. Thromb Res. 2010;125:e259-64 pubmed publisher
    ..maintenance dose in a cohort of patients, using clinical variables and genetic polymorphism in CYP2C9, VKORC1, and CYP4F2. Patients on a stable maintenance dose of warfarin, with observed dose ranging from 0...
  8. Scott S, Khasawneh R, Peter I, Kornreich R, Desnick R. Combined CYP2C9, VKORC1 and CYP4F2 frequencies among racial and ethnic groups. Pharmacogenomics. 2010;11:781-91 pubmed publisher
    b>CYP4F2*3 (p.V433M) has been associated with higher warfarin dose requirements; however, its frequency, like other CYP2C9 and VKORC1 variants, has not been systematically assessed in major racial/ethnic populations...
  9. Kringen M, Haug K, Grimholt R, Stormo C, Narum S, Opdal M, et al. Genetic variation of VKORC1 and CYP4F2 genes related to warfarin maintenance dose in patients with myocardial infarction. J Biomed Biotechnol. 2011;2011:739751 pubmed publisher
    ..was to investigate whether the VKORC1*3 (rs7294/9041 G > A), VKORC1*4 (rs17708472/6009 C > T), and CYP4F2 (rs2108622/1347 C > T) polymorphisms were associated with elevated warfarin maintenance dose requirements ..
  10. Liang R, Li L, Li C, Gao Y, Liu W, Hu D, et al. Impact of CYP2C9*3, VKORC1-1639, CYP4F2rs2108622 genetic polymorphism and clinical factors on warfarin maintenance dose in Han-Chinese patients. J Thromb Thrombolysis. 2012;34:120-5 pubmed publisher
    ..polymorphisms of Cytochrome P450 2C9 (CYP2C9), Vitamin K epoxide reductase complex subunit 1 (VKORC1) and Cytochrome P450 4F2 (CYP4F2) and clinical factors on warfarin maintenance dose in Han-Chinese patients from main land...
  11. Hardwick J. Cytochrome P450 omega hydroxylase (CYP4) function in fatty acid metabolism and metabolic diseases. Biochem Pharmacol. 2008;75:2263-75 pubmed publisher
    ..and inactivation of pro-inflammatory eicosanoids by members of the CYP4F subfamily and the association of the CYP4F2 and CYP4F3 genes with inflammatory celiac disease indicate an important role in the resolution of inflammation...
  12. Fava C, Montagnana M, Almgren P, Rosberg L, Lippi G, Hedblad B, et al. The V433M variant of the CYP4F2 is associated with ischemic stroke in male Swedes beyond its effect on blood pressure. Hypertension. 2008;52:373-80 pubmed publisher
    Cytochrome (CYP) 4A11 and CYP4F2 are responsible for renal production of 20-hydroxyeicosatetraenoic acid, a vasoconstrictor and natriuretic substance...
  13. Pautas E, Moreau C, Gouin Thibault I, Golmard J, Mahe I, Legendre C, et al. Genetic factors (VKORC1, CYP2C9, EPHX1, and CYP4F2) are predictor variables for warfarin response in very elderly, frail inpatients. Clin Pharmacol Ther. 2010;87:57-64 pubmed publisher
    ..7 +/- 6 years. In addition to age, genetic variants of VKORC1, CYP2C9, CYP4F2, and EPHX1 were found to be significant predictor variables for the maintenance dose of warfarin, explaining 26...
  14. Pérez Andreu V, Roldan V, Lopez Fernandez M, Anton A, Alberca I, Corral J, et al. Pharmacogenetics of acenocoumarol in patients with extreme dose requirements. J Thromb Haemost. 2010;8:1012-7 pubmed publisher
    ..We genotyped VKORC1 (rs9923231), CALU (rs1043550), GGCX (rs699664), CYP2C9 (rs1799853; rs1057910), CYP4F2 (rs2108622) and F7 (rs5742910) single-nucleotide polymorphisms (SNPs)...
  15. Bardowell S, Stec D, Parker R. Common variants of cytochrome P450 4F2 exhibit altered vitamin E-{omega}-hydroxylase specific activity. J Nutr. 2010;140:1901-6 pubmed publisher
    Human cytochrome P450 4F2 (CYP4F2) catalyzes the ω-hydroxylation of the side chain of tocopherols (TOH) and tocotrienols (T3), the first step in their catabolism to polar metabolites excreted in urine...
  16. Takeuchi F, McGinnis R, Bourgeois S, Barnes C, Eriksson N, Soranzo N, et al. A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet. 2009;5:e1000433 pubmed publisher
    ..3 x 10(-10)) that alters protein coding of the CYP4F2 gene. We confirmed this result in 588 additional Swedish patients (p<0...
  17. Hayashi H. [Personalized drug therapy-directed clinical pharmacology research based on genetic polymorphisms and pharmacokinetics analysis]. Yakugaku Zasshi. 2013;133:1079-85 pubmed
    ..In addition, we found that the CYP4F2 genotype affects the plasma concentration of menaquinone-4, and that this finding was correlated with the WF ..
  18. Kumar A, Sagar R, Kumar P, Sahu J, Grover A, Srivastava A, et al. Identification of genetic contribution to ischemic stroke by screening of single nucleotide polymorphisms in stroke patients by using a case control study design. BMC Neurol. 2013;13:136 pubmed publisher
    ..reductase (MTHFR), Endothelial Nitric Oxide Synthase (ENOS), Factor V Leiden (F5), Cytochrome P450 4F2 (CYP4F2), beta-fibrinogen and Phosphodiesterase 4D (PDE4D) gene in stroke...
  19. Takitani K, Inoue K, Koh M, Miyazaki H, Kishi K, Inoue A, et al. α-Tocopherol status and altered expression of α-tocopherol-related proteins in streptozotocin-induced type 1 diabetes in rat models. J Nutr Sci Vitaminol (Tokyo). 2014;60:380-6 pubmed publisher
    ..The hepatic expression of cytochrome P450 4F2 (CYP4F2) and CYP3A2 genes in STZ rats also decreased...
  20. Madec S, Cerec V, Plée Gautier E, Antoun J, Glaise D, Salaun J, et al. CYP4F3B expression is associated with differentiation of HepaRG human hepatocytes and unaffected by fatty acid overload. Drug Metab Dispos. 2011;39:1987-96 pubmed publisher
    ..monounsaturated, or polyunsaturated fatty acids, CYP4F3B and CYP4A11 expression remained unchanged whereas CYP4F2 and CYP4F12 expression was transiently up-regulated...
  21. Wu C, Gupta T, Garcia V, Ding Y, Schwartzman M. 20-HETE and blood pressure regulation: clinical implications. Cardiol Rev. 2014;22:1-12 pubmed publisher
    ..numerous polymorphisms in the regulatory coding and noncoding regions of 20-HETE-producing enzymes, CYP4A11 and CYP4F2, have been associated with hypertension...
  22. Sanghera D, Bejar C, Sapkota B, Wander G, Ralhan S. Frequencies of poor metabolizer alleles of 12 pharmacogenomic actionable genes in Punjabi Sikhs of Indian Origin. Sci Rep. 2018;8:15742 pubmed publisher
    ..7% in Europeans (pgenotype = <1.0E-05) and 'T' allele of CYP4F2 (36%) SDS, (43%) GIH, 40% (SAS) vs. (29%) in Europeans (pgenotype = <1...
  23. Daly A. Optimal dosing of warfarin and other coumarin anticoagulants: the role of genetic polymorphisms. Arch Toxicol. 2013;87:407-20 pubmed publisher
    ..these genes together with polymorphisms in other genes relevant to blood coagulation such as the cytochrome P450 CYP4F2, gamma-glutamyl carboxylase, calumenin and cytochrome P450 oxidoreductase may also be significant predictors of ..
  24. Bryk A, Wypasek E, Plens K, Awsiuk M, Undas A. Bleeding predictors in patients following venous thromboembolism treated with vitamin K antagonists: Association with increased number of single nucleotide polymorphisms. Vascul Pharmacol. 2018;106:22-27 pubmed publisher
    ..We assessed eight SNP, including those in cytochrome P450 isoform 2C9 (CYP2C9) and isoform 4F2 (CYP4F2), vitamin K epoxide reductase complex subunit 1 (VKORC1), gamma-glutamyl carboxylase (GGCX), apolipoprotein E (..
  25. Mi J, Zhao M, Yang S, Jia Y, Wang Y, Wang B, et al. Identification of cytochrome P450 isoforms involved in the metabolism of Syl930, a selective S1PR1 agonist acting as a potential therapeutic agent for autoimmune encephalitis. Drug Metab Pharmacokinet. 2017;32:53-60 pubmed publisher
    ..CYP1A1, CYP2J2, CYP4F2 and CYP3A4 were identified to be the major CYPs mediated in the hydroxylation of Syl930 by using 14 recombinant ..
  26. Kumondai M, Ito A, Hishinuma E, Kikuchi A, Saito T, Takahashi M, et al. Development and application of a rapid and sensitive genotyping method for pharmacogene variants using the single-stranded tag hybridization chromatographic printed-array strip (STH-PAS). Drug Metab Pharmacokinet. 2018;33:258-263 pubmed publisher
    ..were in 100% agreement with those obtained using standard Sanger sequencing and KASP assay genotyping methods for CYP4F2 gene deletion...
  27. Cai Y. Arachidonic acid cytochrome P450 4F2 in hypertension: what can we learn from a transgenic mouse model??. Kidney Int. 2009;75:1253-1254 pubmed publisher
    ..Liu et al. report that the CYP4F2 transgene, driven under an exogenous promoter, increases 20-HETE production and is associated with increased blood ..
  28. Xue L, Holford N, Ding X, Shen Z, Huang C, Zhang H, et al. Theory-based pharmacokinetics and pharmacodynamics of S- and R-warfarin and effects on international normalized ratio: influence of body size, composition and genotype in cardiac surgery patients. Br J Clin Pharmacol. 2017;83:823-835 pubmed publisher
    ..Patients with VKORC1 AA and CYP4F2 CC or CT genotypes had lower C50 for S-warfarin...
  29. Santos M, Niemi M, Hiratsuka M, Kumondai M, Ingelman Sundberg M, Lauschke V, et al. Novel copy-number variations in pharmacogenes contribute to interindividual differences in drug pharmacokinetics. Genet Med. 2018;20:622-629 pubmed publisher
    ..We experimentally confirmed novel deletions in CYP2C19, CYP4F2, and SLCO1B3 by Sanger sequencing and validated their allelic frequencies in selected populations...
  30. Tabur S, Oztuzcu S, Oguz E, Demiryürek S, Dağlı H, Alasehirli B, et al. CYP gene expressions in obesity-associated metabolic syndrome. Obes Res Clin Pract. 2016;10:719-723 pubmed publisher
    ..We observed marked suppressions in CYP2A6 (p=0.0123), CYP4F2 (p=0.0005), CYP3A5 (p=0.0003), and CYP17A1 (p<0.0001) gene expressions in MetS patients...
  31. Johnson J, Caudle K, Gong L, Whirl Carrillo M, Stein C, Scott S, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update. Clin Pharmacol Ther. 2017;102:397-404 pubmed publisher
    ..Evidence from the published literature is presented for CYP2C9, VKORC1, CYP4F2, and rs12777823 genotype-guided warfarin dosing to achieve a target international normalized ratio of 2-3 when ..
  32. Nagayoshi H, Kakimoto K, Konishi Y, Kajimura K, Nakano T. Determination of the human cytochrome P450 monooxygenase catalyzing the enantioselective oxidation of 2,2',3,5',6-pentachlorobiphenyl (PCB 95) and 2,2',3,4,4',5',6-heptachlorobiphenyl (PCB 183). Environ Sci Pollut Res Int. 2018;25:16420-16426 pubmed publisher
    ..monooxygenases, namely CYP1A1, CYP1A2, CYP1B1, CYP2A6, CYP2B6, CYP2C8, CYP2C19, CYP2E1, CYP2J2, CYP3A4, CYP3A5, CYP4F2, and aromatase (CYP19), and revealed that CYP2A6 preferably oxidizes aS-PCB 95 enantioselectively; however, it did ..
  33. Dimitrova Karamfilova A, Tzveova R, Chilingirova N, Goranova T, Nachev G, Mitev V, et al. Acenocoumarol Pharmacogenetic Dosing Algorithms and Their Application in Two Bulgarian Patients with Low Anticoagulant Requirements. Biochem Genet. 2015;53:334-50 pubmed publisher
    ..genes for Cytochrome P450 2C9 (CYP2C9), Vitamin K epoxide reductase (VKORC1), Apolipoprotein E (APOE), and Cytochrome P450 4F2 (CYP4F2)...
  34. Li S, Zou Y, Wang X, Huang X, Sun Y, Wang Y, et al. Warfarin dosage response related pharmacogenetics in Chinese population. PLoS ONE. 2015;10:e0116463 pubmed publisher
    ..rs9923231 (VKORC1), rs7294 (VKORC1), rs1057910 (CYP2C9), rs2108622 (CYP4F2), and rs699664 (GGCX) involved in the warfarin action mechanism and the circulatory vitamin K were selected to ..
  35. Xu Z, Zhang S, Huang M, Hu R, Li J, Cen H, et al. Genotype-Guided Warfarin Dosing in Patients With Mechanical Valves: A Randomized Controlled Trial. Ann Thorac Surg. 2018;106:1774-1781 pubmed publisher
    ..randomized control trial was performed to compare a genotype-guided dosing algorithm (CYP2C9, VKORC1, and CYP4F2) with a clinical-guided one in the initiation treatment for patients with mechanical heart valves...
  36. Bartolini D, Torquato P, Barola C, Russo A, Rychlicki C, Giusepponi D, et al. Nonalcoholic fatty liver disease impairs the cytochrome P-450-dependent metabolism of α-tocopherol (vitamin E). J Nutr Biochem. 2017;47:120-131 pubmed publisher
    ..b>CYP4F2 protein, a cytochrome P-450 isoform with proposed α-tocopherol ω-hydroxylase activity, decreased in HFD and even ..
  37. Ivashchenko D, Rusin I, Sychev D, Grachev A. The frequency of CYP2C9, VKORC1, and CYP4F2 polymorphisms in Russian patients with high thrombotic risk. Medicina (Kaunas). 2013;49:517-21 pubmed
    VKORC1, CYP2C9, and CYP4F2 are known to be responsible for the metabolism of warfarin. The aim was to explore the frequencies of these genotypes in the Russian population and compare the results with those for other populations...
  38. Dai D, Li C, Wang S, Cai J, Geng P, Zhou Y, et al. Identification and characterization of a novel CYP2C9 allelic variant in a warfarin-sensitive patient. Pharmacogenomics. 2015;16:1475-86 pubmed publisher
    ..Bi-directional sequencing of CYP2C9, VKORC1 and CYP4F2 genes was performed. CYP2C9 variants were highly expressed in yeast and insect-cell microsomes...
  39. Sontag T, Parker R. Influence of major structural features of tocopherols and tocotrienols on their omega-oxidation by tocopherol-omega-hydroxylase. J Lipid Res. 2007;48:1090-8 pubmed
    Human cytochrome P450 4F2 (CYP4F2) catalyzes the initial omega-hydroxylation reaction in the metabolism of tocopherols and tocotrienols to carboxychromanols and is, to date, the only enzyme shown to metabolize vitamin E...
  40. Fan F, Muroya Y, Roman R. Cytochrome P450 eicosanoids in hypertension and renal disease. Curr Opin Nephrol Hypertens. 2015;24:37-46 pubmed publisher
    ..Mutations in CYP4A11 and CYP4F2 have been linked to elevated BP in humans...
  41. Kawai V, Cunningham A, Vear S, Van Driest S, Oginni A, Xu H, et al. Genotype and risk of major bleeding during warfarin treatment. Pharmacogenomics. 2014;15:1973-83 pubmed publisher
    ..Using Vanderbilt's DNA biobank we compared the prevalence of CYP2C9, VKORC1 and CYP4F2 variants in 250 cases with major bleeding and 259 controls during warfarin therapy...
  42. Sun Y, Wu Z, Li S, Qin X, Li T, Xie L, et al. Impact of gamma-glutamyl carboxylase gene polymorphisms on warfarin dose requirement: a systematic review and meta-analysis. Thromb Res. 2015;135:739-47 pubmed publisher
    ..GGCX) gene, as with Vitamin K Epoxide Reductase Complex Subunit 1 (VKORC1), CytochromeP450 Complex Subunit 14 F2 (CYP4F2) and CytochromeP450 Complex Subunit2C9 (CYP2C9), is a candidate predictor for appropriate maintenance warfarin ..
  43. Teichert M, Eijgelsheim M, Rivadeneira F, Uitterlinden A, van Schaik R, Hofman A, et al. A genome-wide association study of acenocoumarol maintenance dosage. Hum Mol Genet. 2009;18:3758-68 pubmed publisher
    ..3 x 10(-24)). After adjustment for these SNPs, the rs2108622 polymorphism within cytochrome P450 4F2 (CYP4F2) gene on chromosome 19 reached genome-wide significance (P = 2.0 x 10(-8))...
  44. Ichimura Y, Takahashi H, Lee M, Shiomi M, Mihara K, Morita T, et al. Inter-individual differences in baseline coagulation activities and their implications for international normalized ratio control during warfarin initiation therapy. Clin Pharmacokinet. 2012;51:799-808 pubmed publisher
    ..warfarin therapy for up to 3 months and analysed functional single nucleotide polymorphisms (SNPs) of VKORC1 and CYP4F2 in 179 Chinese patients. The patients were classified into tertile groups according to NPT(0) values (i.e...
  45. Kim W, Lee S, Min J, Oh K, Kim D, Kim H, et al. Identification of novel CYP4F2 genetic variants exhibiting decreased catalytic activity in the conversion of arachidonic acid to 20-hydroxyeicosatetraenoic acid (20-HETE). Prostaglandins Leukot Essent Fatty Acids. 2018;131:6-13 pubmed publisher
    b>CYP4F2 is an enzyme involved in the formation of 20-hydroxyeicosatetraenoic acid (20-HETE) from arachidonic acid and metabolizes vitamin K into an inactive form...
  46. Wei M, Ye F, Xie D, Zhu Y, Zhu J, Tao Y, et al. A new algorithm to predict warfarin dose from polymorphisms of CYP4F2 , CYP2C9 and VKORC1 and clinical variables: derivation in Han Chinese patients with non valvular atrial fibrillation. Thromb Haemost. 2012;107:1083-91 pubmed publisher
    ..The objective of this study was to develop a new algorithm by polymorphisms of CYP2C9, VKORC1 and CYP4F2 to predict the daily stable dose of warfarin in Chinese patients with NVAF...
  47. Li J, Yang W, Xie Z, Yu K, Chen Y, Cui K. Impact of VKORC1, CYP4F2 and NQO1 gene variants on warfarin dose requirement in Han Chinese patients with catheter ablation for atrial fibrillation. BMC Cardiovasc Disord. 2018;18:96 pubmed publisher
    ..We aimed to assess impact of three important genes participating in vitamin K cycle (i.e. VKORC1 rs9923231, CYP4F2 rs2108622 and NQO1 rs1800566) on the daily stable warfarin dose requirement in Sichuan Han Chinese patients with ..
  48. Yang D, Kuang H, Zhou Y, Cai C, Lu T. Height, VKORC1 1173, and CYP2C9 Genotypes Determine Warfarin Dose for Pediatric Patients with Kawasaki Disease in Southwest China. Pediatr Cardiol. 2019;40:29-37 pubmed publisher
    ..The relevant genotypes of CYP2C9, VKORC1 (1173, - 1639, and 3730), and CYP4F2 were assessed...
  49. Cerezo Manchado J, Roldan V, Corral J, Rosafalco M, Antón A, Padilla J, et al. Genotype-guided therapy improves initial acenocoumarol dosing. Results from a prospective randomised study. Thromb Haemost. 2016;115:117-25 pubmed publisher
    ..dose was calculated based on INR in the standard care group (SC, N=92), whereas genetic data (VKORC1, CYP2C9 and CYP4F2) were also considered for the genotype-guided dosing (pharmacogenetic) group (PGx, N=87) by using an algorithm ..
  50. Quinn A, Liko I, Lee J. Clinical effect of CYP2C9*5/*6 genotype on a patient's warfarin dose requirement. Pharmacogenomics. 2017;18:1051-1057 pubmed publisher
    ..pulmonary emboli who is a carrier of two rare CYP2C9 variant alleles, *5 and *6, along with VKORC1 -1639GG and CYP4F2 433Val/Val genotypes...
  51. Rathore S, Agarwal S, Pande S, Singh S, Mittal T, Mittal B. CYP4F2 1347 G > A & GGCX 12970 C > G polymorphisms: frequency in north Indians & their effect on dosing of acenocoumarol oral anticoagulant. Indian J Med Res. 2014;139:572-8 pubmed
    b>CYP4F2 and γ-glutamyl carboxylase (GGCX) have small but significant roles in the maintenance dose of coumarinic oral anticoagulants (COAs)...
  52. Gage B, Bass A, Lin H, Woller S, Stevens S, Al Hammadi N, et al. Effect of Genotype-Guided Warfarin Dosing on Clinical Events and Anticoagulation Control Among Patients Undergoing Hip or Knee Arthroplasty: The GIFT Randomized Clinical Trial. JAMA. 2017;318:1115-1124 pubmed publisher
    ..Patients were genotyped for the following polymorphisms: VKORC1-1639G>A, CYP2C9*2, CYP2C9*3, and CYP4F2 V433M...
  53. Plenty N, Faulkner J, Cotton J, Spencer S, Wallace K, LaMarca B, et al. Arachidonic acid metabolites of CYP4A and CYP4F are altered in women with preeclampsia. Prostaglandins Other Lipid Mediat. 2018;136:15-22 pubmed publisher
    ..CYP450 isoform expression (CYP4A11, CYP4A22, CYP4F2, and CYP4F3) was found to be elevated within the placenta of women with PE compared to normal pregnant (NP) women ..
  54. Nagata T, Takahashi Y, Ishii Y, Asai S, Sugahara M, Nishida Y, et al. Profiling of genes differentially expressed between fetal liver and postnatal liver using high-density oligonucleotide DNA array. Int J Mol Med. 2003;11:713-21 pubmed
    ..signals (AR, SRD5A1, NR1I3), and cellular metabolism (E2-EPF, WWP1, CYP2C9, CYP2E1, CYP2A6, CYP2A7, CYP2A13, CYP4F2, CYP3A4, DDT)...
  55. Bourgeois S, Jorgensen A, Zhang E, Hanson A, Gillman M, Bumpstead S, et al. A multi-factorial analysis of response to warfarin in a UK prospective cohort. Genome Med. 2016;8:2 pubmed publisher
    ..VKORC1 and CYP2C9 were the major genetic determinants of warfarin MWD and SMWD, with CYP4F2 having a smaller effect...
  56. Perini J, Struchiner C, Silva Assunção E, Suarez Kurtz G. Impact of CYP4F2 rs2108622 on the stable warfarin dose in an admixed patient cohort. Clin Pharmacol Ther. 2010;87:417-20 pubmed publisher
    There is controversy regarding the association between the CYP4F2 rs2108622 (V33M) polymorphism and warfarin dose requirement in white patients, and there are no data for nonwhite populations...
  57. Steuck M, Hellhake S, Schebb N. Food Polyphenol Apigenin Inhibits the Cytochrome P450 Monoxygenase Branch of the Arachidonic Acid Cascade. J Agric Food Chem. 2016;64:8973-8976 pubmed
    ..Apigenin inhibits CYP4F2 with an IC50 value of 4.6 μM and 20-HETE formation in human liver and kidney microsomes at 2.4-9.8 μM...
  58. Wattanachai N, Kaewmoongkun S, Pussadhamma B, Makarawate P, Wongvipaporn C, Kiatchoosakun S, et al. The impact of non-genetic and genetic factors on a stable warfarin dose in Thai patients. Eur J Clin Pharmacol. 2017;73:973-980 pubmed publisher
    ..Four single nucleotide polymorphisms in the VKORC1 - 1639G > A, CYP2C9*3, CYP4F2 rs2108622, and UGT1A1 rs887829 genes were detected from gDNA using TaqMan allelic discrimination assays...
  59. Fu Z, Nakayama T, Sato N, Izumi Y, Kasamaki Y, Shindo A, et al. A haplotype of the CYP4F2 gene is associated with cerebral infarction in Japanese men. Am J Hypertens. 2008;21:1216-23 pubmed publisher
    b>CYP4F2, a member of the cytochrome P450 family, acts mainly as an enzyme and is involved not only in the metabolism of leukotriene B4, but also in that of arachidonic acid...
  60. Li J, Ma G, Zhu S, Yan H, Wu Y, Xu J. Correlation between single nucleotide polymorphisms in CYP4F2 and warfarin dosing in Chinese valve replacement patients. J Cardiothorac Surg. 2012;7:97 pubmed publisher
    ..Our aim was to study the effect of the CYP4F2 rs2108622-1347 (C > T) variant on warfarin dosing in Chinese patients...
  61. Wypasek E, Branicka A, Awsiuk M, Sadowski J, Undas A. Genetic determinants of acenocoumarol and warfarin maintenance dose requirements in Slavic population: a potential role of CYP4F2 and GGCX polymorphisms. Thromb Res. 2014;134:604-9 pubmed publisher
    ..b>Cytochrome P450 4F2 isoform (CYP4F2), gamma-glutamyl carboxylase (GGCX) and apolipoprotein E (APOE) polymorphisms have been ..
  62. Shaw K, Amstutz U, Kim R, Lesko L, Turgeon J, Michaud V, et al. Clinical Practice Recommendations on Genetic Testing of CYP2C9 and VKORC1 Variants in Warfarin Therapy. Ther Drug Monit. 2015;37:428-36 pubmed publisher
    ..Testing for CYP2C9*5, *6, *8, or *11 and CYP4F2 (V433M) is currently not recommended...
  63. Chung J, Lee K, Chang B, Gwak H. Polymorphisms of vitamin K-related genes (EPHX1 and VKORC1L1) and stable warfarin doses. Gene. 2018;641:68-73 pubmed publisher
    ..polymorphisms (SNPs) in 201 patients with stable warfarin doses were analyzed including genes of VKORC1, CYP2C9, CYP4F2, GGCX, EPHX1 and VKORC1L1...
  64. Haga S, Miyaji M, Nakano M, Ishizaki H, Matsuyama H, Katoh K, et al. Changes in the expression of α-tocopherol-related genes in liver and mammary gland biopsy specimens of peripartum dairy cows. J Dairy Sci. 2018;101:5277-5293 pubmed publisher
    ..transporter A1; tocopherol-associated protein (SEC14L2); and cytochrome P450 family 4, subfamily F, polypeptide 2 (CYP4F2)] are expressed in liver and other peripheral tissues...
  65. Pathare A, Al Zadjali S, Misquith R, Alkindi S, Panjwani V, Lapoumeroulie C, et al. Warfarin pharmacogenetics: polymorphisms of the CYP2C9, CYP4F2, and VKORC1 loci in a genetically admixed Omani population. Hum Biol. 2012;84:67-77 pubmed publisher
    ..is the first study to evaluate the spectrum and prevalence of dose-predictive genetic polymorphisms of the CYP2C9, CYP4F2 and VKORC1 loci together, in a geographically defined, ethnically admixed healthy adult Omani population sharing ..
  66. Danese E, Montagnana M, Johnson J, Rettie A, Zambon C, Lubitz S, et al. Impact of the CYP4F2 p.V433M polymorphism on coumarin dose requirement: systematic review and meta-analysis. Clin Pharmacol Ther. 2012;92:746-56 pubmed publisher
    ..performed to quantify the accumulated information from genetic association studies investigating the impact of the CYP4F2 rs2108622 (p.V433M) polymorphism on coumarin dose requirement...
  67. Hirai K, Yamada Y, Hayashi H, Tanaka M, Izumiya K, Suzuki M, et al. Plasma vitamin K concentrations depend on CYP4F2 polymorphism and influence on anticoagulation in Japanese patients with warfarin therapy. Thromb Res. 2015;135:861-6 pubmed publisher
    ..This study aimed to analyze the contribution of the CYP4F2 genetic polymorphism and plasma vitamin K concentration on the warfarin pharmacodynamics in patients and to ..
  68. Wakamiya T, Hokosaki T, Tsujimoto S, Kadota K, Nakano Y, Watanabe S, et al. Effect of VKORC1, CYP2C9, CFP4F2, and GGCX Gene Polymorphisms on Warfarin Dose in Japanese Pediatric Patients. Mol Diagn Ther. 2016;20:393-400 pubmed publisher
    ..polymorphisms on stable warfarin dosage requirement was investigated by genotyping SNPs of the VKORC1, CYP2C9, CYP4F2, and GGCX genes (rs9923231, rs1057910, rs2108622, and rs699664, respectively) in each patient...
  69. Zhang B, Lai G, Wu J, Sun R, Xu R, Yang X, et al. 20-HETE attenuates the response of glucose-stimulated insulin secretion through the AKT/GSK-3β/Glut2 pathway. Endocrine. 2016;54:371-382 pubmed
    We previously generated cytochrome P450 4F2 (CYP4F2) transgenic mice that have high levels of 20-hydroxyeicosatetraenoic acid (20-HETE) production; these mice exhibit both hypertension and hyperglycemia without insulin resistance...
  70. Pathare A, Al Khabori M, AlKindi S, Al Zadjali S, Misquith R, Khan H, et al. Warfarin pharmacogenetics: development of a dosing algorithm for Omani patients. J Hum Genet. 2012;57:665-9 pubmed publisher
    ..We studied the functional polymorphisms of CYP2C9, CYP4F2 and VKORC1 genes to evaluate their impact on the warfarin maintenance dose in an admixed Omani patient cohort with ..
  71. Fohner A, Robinson R, Yracheta J, Dillard D, Schilling B, Khan B, et al. Variation in genes controlling warfarin disposition and response in American Indian and Alaska Native people: CYP2C9, VKORC1, CYP4F2, CYP4F11, GGCX. Pharmacogenet Genomics. 2015;25:343-353 pubmed publisher
    ..Therefore, we were interested in variation in CYP2C9, VKORC1, CYP4F2, CYP4F11, and GGCX, which encode enzymes important for the activity of warfarin and synthesis of vitamin K-..
  72. Chung J, Chang B, Lee K, Kim J, Gwak H. Effects of NAD(P)H quinone oxidoreductase 1 polymorphisms on stable warfarin doses in Korean patients with mechanical cardiac valves. Eur J Clin Pharmacol. 2015;71:1229-36 pubmed publisher
    ..Also, genotypes of vitamin K epoxide reductase complex subunit 1 (VKORC1), cytochrome P450 (CYP) 2C9, CYP4F2, gamma-glutamyl carboxylase (GGCX), and GATA4 were determined...
  73. Pratt V, Everts R, Aggarwal P, Beyer B, Broeckel U, EPSTEIN BAAK R, et al. Characterization of 137 Genomic DNA Reference Materials for 28 Pharmacogenetic Genes: A GeT-RM Collaborative Project. J Mol Diagn. 2016;18:109-23 pubmed publisher
    ..testing assays (CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4, CYP3A5, CYP4F2, DPYD, GSTM1, GSTP1, GSTT1, NAT1, NAT2, SLC15A2, SLC22A2, SLCO1B1, SLCO2B1, TPMT, UGT1A1, UGT2B7, UGT2B15, UGT2B17,..
  74. Wang L, Ding L, Yu Z, Zhang T, Ma S, Liu J. Intracellular ROS scavenging and antioxidant enzyme regulating capacities of corn gluten meal-derived antioxidant peptides in HepG2 cells. Food Res Int. 2016;90:33-41 pubmed publisher
    ..assay was used to assess their antioxidant activities and revealed that both CPF1 (molecular weight <1kDa) and CPF2 (molecular weight between 1 and 3kDa) exhibited high cellular antioxidant activities with EC50 values of ..
  75. Shendre A, Brown T, Liu N, Hill C, Beasley T, Nickerson D, et al. Race-Specific Influence of CYP4F2 on Dose and Risk of Hemorrhage Among Warfarin Users. Pharmacotherapy. 2016;36:263-72 pubmed publisher
    The p.V433M in cytochrome P450 4F2 (rs2108622, CYP4F2*3) is associated with a higher warfarin dose and lower risk of hemorrhage among European Americans...
  76. Pérez Andreu V, Roldan V, Antón A, García Barberá N, Corral J, Vicente V, et al. Pharmacogenetic relevance of CYP4F2 V433M polymorphism on acenocoumarol therapy. Blood. 2009;113:4977-9 pubmed publisher
    VKORC1 and CYP2C9 polymorphisms are used to predict the safe dose of oral anticoagulant therapy. A new variant of CYP4F2 (V433M) has recently been related to the required warfarin dose...
  77. Hu B, Li Y, Li F, Zhang Y, Sheng C, Fan H, et al. Peripheral and central augmentation indexes in relation to the CYP4F2 polymorphisms in Chinese. J Hypertens. 2011;29:501-8 pubmed publisher
    ..We, therefore, investigated the CYP4F2 polymorphisms in relation to arterial wave reflections, as measured by augmentation indexes (AIx) in Chinese...
  78. Scott S, Patel M, Martis S, Lubitz S, van der Zee S, Yoo C, et al. Copy number variation and warfarin dosing: evaluation of CYP2C9, VKORC1, CYP4F2, GGCX and CALU. Pharmacogenomics. 2012;13:297-307 pubmed publisher
    To determine if copy number variants contribute to warfarin dose requirements, we investigated CYP2C9, VKORC1, CYP4F2, GGCX and CALU for deletions and duplications in a multiethnic patient population treated with therapeutic doses of ..
  79. Rusdiana T, Araki T, Nakamura T, Subarnas A, Yamamoto K. Responsiveness to low-dose warfarin associated with genetic variants of VKORC1, CYP2C9, CYP2C19, and CYP4F2 in an Indonesian population. Eur J Clin Pharmacol. 2013;69:395-405 pubmed publisher
    ..and pharmacodynamics of warfarin associated with genetic polymorphisms in VKORC1, CYP2C9, CYP2C19, and CYP4F2 in Indonesian patients treated with low-dose warfarin...
  80. Alvarellos M, Sangkuhl K, Daneshjou R, Whirl Carrillo M, Altman R, Klein T. PharmGKB summary: very important pharmacogene information for CYP4F2. Pharmacogenet Genomics. 2015;25:41-7 pubmed publisher
  81. Gonzalez Covarrubias V, Urena Carrion J, Villegas Torres B, Cossío Aranda J, Trevethan Cravioto S, Izaguirre Avila R, et al. Pharmacogenetic Variation in Over 100 Genes in Patients Receiving Acenocumarol. Front Pharmacol. 2017;8:863 pubmed publisher
    ..We report relevant population differentiation for variants on CYP2C8, CYP2C19, CYP4F11, CYP4F2, PROS, and GGCX, VKORC1, CYP2C18, NQO1...
  82. Zhang J, Jorgensen A, Alfirevic A, Williamson P, Toh C, Park B, et al. Effects of CYP4F2 genetic polymorphisms and haplotypes on clinical outcomes in patients initiated on warfarin therapy. Pharmacogenet Genomics. 2009;19:781-9 pubmed publisher
    A variant in the CYP4F2 gene, rs2108622, has been recently shown to determine stable warfarin dose requirements. CYP4F2 has also been shown recently to metabolize vitamin K...
  83. Cerezo Manchado J, Roldan V, Rosafalco M, Antón A, Arroyo A, García Barberá N, et al. Effect of VKORC1, CYP2C9 and CYP4F2 genetic variants in early outcomes during acenocoumarol treatment. Pharmacogenomics. 2014;15:987-96 pubmed publisher
    To analyze VKORC1, CYP2C9 and CYP4F2 polymorphisms in relation to the main outcomes in the first stages of acenocoumarol therapy...
  84. Yu C, Yan Q, Fu C, Shi W, Wang H, Zeng C, et al. CYP4F2 genetic polymorphisms are associated with coronary heart disease in a Chinese population. Lipids Health Dis. 2014;13:83 pubmed publisher
    To explore the relationship between CYP4F2 gene polymorphism and coronary heart disease (CHD) in a Chinese Han population. We selected 440 CHD patients and 440 control subjects to perform a case - control study...
  85. Russo A, Bartolini D, Torquato P, Giusepponi D, Barola C, Galarini R, et al. CYP4F2 repression and a modified alpha-tocopherol (vitamin E) metabolism are two independent consequences of ethanol toxicity in human hepatocytes. Toxicol In Vitro. 2017;40:124-133 pubmed publisher
    The expression of CYP4F2, a form of cytochrome P-450 with proposed role in ?-tocopherol and long-chain fatty acid metabolism, was explored in HepG2 and HepaRG human hepatocytes during ethanol toxicity...
  86. Giri A, Khan N, Grover S, Kaur I, Basu A, Tandon N, et al. Genetic epidemiology of pharmacogenetic variations in CYP2C9, CYP4F2 and VKORC1 genes associated with warfarin dosage in the Indian population. Pharmacogenomics. 2014;15:1337-54 pubmed publisher
    ..5% in an out-group subpopulation to >70% in Tibeto-Burmans. Risk allele frequency of CYP4F2*3 (V433M) was higher in north Indians (0.30-0...
  87. Santhanam G, Yu B, Gilja V, Ryu S, Afshar A, Sahani M, et al. Factor-analysis methods for higher-performance neural prostheses. J Neurophysiol. 2009;102:1315-30 pubmed publisher
    ..We propose that FA-based methods are effective in modeling correlated trial-to-trial neural variability and can be used to substantially increase overall prosthetic system performance. ..
  88. Major J, Yu K, Wheeler W, Zhang H, Cornelis M, Wright M, et al. Genome-wide association study identifies common variants associated with circulating vitamin E levels. Hum Mol Genet. 2011;20:3876-83 pubmed publisher
    ..3 near BUD13, ZNF259 and APOA1/C3/A4/A5), P= 1.4 × 10(-10) (rs2108622 on 19pter-p13.11 near CYP4F2) and P= 8.2 × 10(-9) (rs11057830 on 12q24.31 near SCARB1). Combined, these SNPs explain 1...
  89. Ward N, Croft K, Puddey I, Phillips M, van Bockxmeer F, Beilin L, et al. The effect of a single nucleotide polymorphism of the CYP4F2 gene on blood pressure and 20-hydroxyeicosatetraenoic acid excretion after weight loss. J Hypertens. 2014;32:1495-502; discussion 1502 pubmed publisher
    Genetic background partly determines the efficacy of interventions to lower blood pressure (BP). The CYP4F2 and CYP4A11 enzymes are renal 20-hydroxyeicosatetraenoic acid (20-HETE) synthases that regulate BP...
  90. Dashti H, Shea M, Smith C, Tanaka T, Hruby A, Richardson K, et al. Meta-analysis of genome-wide association studies for circulating phylloquinone concentrations. Am J Clin Nutr. 2014;100:1462-9 pubmed publisher
    ..near the candidate genes APOA1/C3/A4/A5 cluster (involved in lipoprotein metabolism), COL22A1, CDO1, CTNAA2, and CYP4F2 (a phylloquinone oxidase), respectively...
  91. Sipeky C, Weber A, Melegh B, Matyas P, Janicsek I, Szalai R, et al. Interethnic variability of CYP4F2 (V433M) in admixed population of Roma and Hungarians. Environ Toxicol Pharmacol. 2015;40:280-3 pubmed publisher
    ..difference in dosing algorithms of under-represented populations forced us to explore the genetic variability of CYP4F2 gene in Roma and Hungarian populations...
  92. Chen P, Sun Y, Yang G, Li R, Pan J, Zhou Y. Influence of the CYP4F2 polymorphism on the risk of hemorrhagic complications in coumarin-treated patients. Saudi Med J. 2016;37:361-8 pubmed publisher
    To evaluate the impact of the CYP4F2 polymorphism on bleeding complications and over-anticoagulation due to coumarin...